EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for High-Risk breast cancer: immune booster after chemo may keep cancer away
Disease control Not yet recruitingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard post-surgery treatment can prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1000…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated May 17, 2026 05:52 UTC
-
Gut bacteria boosts breast cancer treatment? new trial launches
Disease control Not yet recruitingThis phase 2 trial tests whether adding a live bacteria supplement (MO-03) to standard chemotherapy and immunotherapy (pembrolizumab) can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants take the supplement twice daily until surgery, the…
Matched conditions: EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 17, 2026 05:48 UTC